Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

It's a Man's Man's Man's World – What's needed for better CVD drugs for women?

This article was originally published in Scrip

Executive Summary

Each year over 8.6 million women die of heart disease and stroke, making heart disease the number one cause of death for women globally, but while men and woman are equally affected by cardiovascular disease (CVD) the drugs on the market are largely designed from clinical studies testing efficacy and dosage for men. What's more, in the US at least, adverse drug reactions occur approximately twice as often in women as in men.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC024676

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel